820 related articles for article (PubMed ID: 27936119)
1. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
[TBL] [Abstract][Full Text] [Related]
2. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis.
Kui R; Gál B; Gaál M; Kiss M; Kemény L; Gyulai R
J Dermatol; 2016 Sep; 43(9):1018-23. PubMed ID: 26892625
[TBL] [Abstract][Full Text] [Related]
3. Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab.
Bissonnette R; Maari C; Barber K; Lynde CW; Vender R
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1576-81. PubMed ID: 25600828
[TBL] [Abstract][Full Text] [Related]
4. Determination of adalimumab and etanercept trough levels and drug antibodies in long-term psoriasis treatment: a single-centre cohort study.
Manriquez J; Alsina-Gibert M
Clin Exp Dermatol; 2017 Jan; 42(1):14-20. PubMed ID: 27943384
[TBL] [Abstract][Full Text] [Related]
5. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
Mössner R; Reich K
Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
[TBL] [Abstract][Full Text] [Related]
6. Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors.
Tragiannidis A; Kyriakidis I; Zündorf I; Groll AH
Mycoses; 2017 Apr; 60(4):222-229. PubMed ID: 27766695
[TBL] [Abstract][Full Text] [Related]
7. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
Potenza MC; Peris K; Berardesca E; Bianchi L; Richetta A; Bernardini N; De Simone C; Teoli M; Zangrilli A; D'epiro S; Orsini D; Narcisi A; Chimenti S; Costanzo A
Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
[TBL] [Abstract][Full Text] [Related]
8. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study.
Kyriakou A; Patsatsi A; Sotiriadis D
J Dermatolog Treat; 2013 Jun; 24(3):162-8. PubMed ID: 22136334
[TBL] [Abstract][Full Text] [Related]
9. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
10. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis.
Tan E; Baker C; Foley P
Australas J Dermatol; 2013 Nov; 54(4):259-63. PubMed ID: 24164178
[TBL] [Abstract][Full Text] [Related]
11. Clinical predictors of nonresponse to anti-TNF-α agents in psoriatic patients: A retrospective study.
De Simone C; Caldarola G; Maiorino A; Tassone F; Campana I; Sollena P; Peris K
Dermatol Ther; 2016 Sep; 29(5):372-376. PubMed ID: 27146358
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring of patients with psoriasis during tumour necrosis factor (TNF)-α antagonist treatment using a novel interleukin-8 reporter cell line.
Kimura Y; Shimada-Omori R; Takahashi T; Tsuchiyama K; Kusakari Y; Yamasaki K; Nishikawa R; Nishigori C; Aiba S
Br J Dermatol; 2016 Nov; 175(5):979-987. PubMed ID: 27155194
[TBL] [Abstract][Full Text] [Related]
13. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
Cozzani E; Burlando M; Parodi A
G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
[TBL] [Abstract][Full Text] [Related]
15. Drug concentration and antidrug antibodies in patients with psoriasis treated with adalimumab or etanercept.
Gyldenløve M; Zachariae C; Jensen P; Griehsel H; Ståhle M; Skov L
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):e518-e519. PubMed ID: 28557009
[No Abstract] [Full Text] [Related]
16. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
[TBL] [Abstract][Full Text] [Related]
17. Ustekinumab in patients previously treated with TNFα inhibitors: a real-life study.
Pinheiro RR; Duarte B; Ferreira A; Cabete J
Eur J Dermatol; 2018 Feb; 28(1):89-91. PubMed ID: 29400282
[No Abstract] [Full Text] [Related]
18. Antidrug antibodies in psoriasis: a systematic review.
Hsu L; Snodgrass BT; Armstrong AW
Br J Dermatol; 2014 Feb; 170(2):261-73. PubMed ID: 24117166
[TBL] [Abstract][Full Text] [Related]
19. Changes in serum TNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments.
Engin B; Tanakol A; Bulut H; Songür A; Vehid HE; Gökalp E; Kutlubay Z; Özkoca D; Tüzün Y; Serdaroğlu S
Int J Dermatol; 2020 Feb; 59(2):207-215. PubMed ID: 31531981
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]